Testcard Debuts Non-Invasive Diagnostic Solutions at MEDICA

By Michael Barbella, Managing Editor | 11.15.23

U.K. company has also developed advanced technical solutions for patient screening.

U.K.-based diagnostics technology company TestCard is unveiling its non-invasive diagnostic solutions this week at MEDICA, the world's largest medical trade show. 

Designed to make testing more accessible for consumers and in clinical settings, TestCard's technology transforms a mobile device into a clinical-grade scanner. At MEDICA, the company is showcasing its three primary areas of focus, including an at-home UTI test kit with an accuracy comparable to urine tests performed in clinical settings. When coupled with the smartphone app, it allows users to obtain immediate accurate test results from the comfort of their own home. The technology directly integrates with individual suppliers to maintain a complete end-to-end pathway, back to the supplier for treatment. 
TestCard has also developed advanced technical solutions for patient screening, helping identify individuals at risk of serious illnesses. By streamlining the process and enabling at-risk patients to test at home, healthcare providers can promptly allocate resources to those in need, optimising GP and laboratory time.
In collaboration with Guys & St Thomas NHS Foundation Trust (GSTT), the company has launched the ClearScreen technology that digitalizes point-of-care rapid diagnostic testing, including lateral flow tests. The ClearScreen app immediately records patients’ test results digitally and transmits them to the electronic patient record (EPR) in seconds, giving clinical teams real-time results. TestCard's expanding test portfolio includes Single Covid, Covid/Flu dual test, Covid/Flu/RSV Triple test, Single RSV, Pregnancy, Strep A, CRP, D-Dimer, Troponin, and Monkeypox, contributing to quicker, more efficient healthcare pathways.
“Rapid diagnostic testing helps to ease the pressures on health systems," TestCard Chief Scientific Officer Dr. Andrew Botham said. "Test results can be generated sooner and acted upon immediately, while mitigating risk for everyone. It also improves the patient pathway with a more effective patient triage, reducing delays with test results. TestCard is excited to be joining ABHI at MEDICA 2023 to showcase our range of technologies designed to transform the fast-growing field of diagnostics, and we look forward to connecting with partners in the region.”
TestCard's platform technology reduces the need for traditional testing, reducing the hassle of multiple appointments, lengthy wait times, and lab fees. The focus on immediacy and accessibility empowers users to receive accurate test results at home or in clinical settings while seamlessly integrating into electronic patient record systems for effective treatment.
In the last year, TestCard has signed a major partnership agreement with Roche Diagnostics. Its technology has also garnered recognition, with TestCard winning multiple awards, including the Digital Health Award, the Shift.ms Digital Award, and the Royal Society of Chemistry Emerging Technologies Competition.
TestCard creates at-home testing that provides immediate results at a low cost. TestCard is a combination of non-invasive, postcard-sized urine test kits and a mobile phone app that turns a smartphone camera into a clinical grade scanner. 
TestCard's full range of diagnostic solutions is on display at its booth at the ABHI UK Pavilion, Hall 16 Stand 16J60.5. MEDICA is taking place through Nov. 16 in Düsseldorf, Germany.